Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Conditions:   Hepatocellular Carcinoma Non-resectable;   Portal Vein Tumor Thrombus;   Immune Checkpoint Inhibitors Interventions:   Drug: Cadonilimab;   Radiation: Stereotactic radiotherapy;   Drug: Renvatinib Sponsor:   First Affiliated Hospital of Guangxi Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials